ZOCOR (simvastatin) by Merck & Co. is hydroxymethylglutaryl-coa reductase inhibitors [moa]. First approved in 1991.
Drug data last refreshed 5h ago · AI intelligence enriched 6d ago
ZOCOR (simvastatin) is an oral HMG-CoA reductase inhibitor (statin) approved in 1991 that lowers cholesterol by inhibiting a key enzyme in hepatic cholesterol synthesis. It is indicated for reduction of elevated cholesterol levels in patients at risk for cardiovascular disease. The drug remains a foundational therapy in preventive cardiology across multiple risk categories.
Aging brand in final generic-exposed lifecycle phase with minimal Part D spending signals consolidating commercial infrastructure and diminished promotional resource allocation.
Hydroxymethylglutaryl-CoA Reductase Inhibitors
HMG-CoA Reductase Inhibitor
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants
Simvastatin Treatment to Improve Patient-reported Outcomes in Patients With Chronic Pancreatitis
Bioequivalence Study of Simvastatin 40 mg Film-coated Tablets in Healthy Thai Volunteers
Effect of Repeated Oral Doses of Avacopan on the Pharmacokinetics (PK) of a Single Dose of Simvastatin
Drug-Drug Interaction Study to Investigate Effects of Voclosporin on Pharmacokinetics of Simvastatin
Worked on ZOCOR at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on ZOCOR offers limited career growth opportunity given its post-LOE lifecycle and commoditized market position; roles focus on payer management, cost containment, and regulatory maintenance rather than innovation or expansion. This assignment is typically suited for early-career professionals gaining general pharma operations experience or specialists in generic portfolio management rather than those seeking brand-building or clinical leadership exposure.